JPMorgan Chase & Co. assumed coverage on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a report issued on Monday morning, The Fly reports. The brokerage issued an overweight rating and a $175.00 price target on the specialty pharmaceutical company’s stock.

Other equities research analysts have also recently issued research reports about the company. Barclays reissued a buy rating on shares of Jazz Pharmaceuticals in a research note on Thursday, August 6th. HC Wainwright upgraded Jazz Pharmaceuticals from a neutral rating to a buy rating and upped their target price for the company from $145.00 to $166.00 in a research report on Thursday, July 23rd. Goldman Sachs Group lowered Jazz Pharmaceuticals from a neutral rating to a sell rating and set a $128.00 target price on the stock. in a research report on Monday. BidaskClub upgraded Jazz Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, September 1st. Finally, Wolfe Research upgraded Jazz Pharmaceuticals from a peer perform rating to an outperform rating in a research report on Tuesday, July 28th. Two analysts have rated the stock with a sell rating, two have given a hold rating and sixteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average target price of $161.81.

Shares of JAZZ stock opened at $140.15 on Monday. The stock has a market cap of $7.77 billion, a price-to-earnings ratio of 60.67, a PEG ratio of 1.39 and a beta of 1.26. The stock has a 50-day moving average of $127.17 and a 200-day moving average of $114.00. The company has a current ratio of 5.62, a quick ratio of 5.39 and a debt-to-equity ratio of 0.66. Jazz Pharmaceuticals has a 1-year low of $86.88 and a 1-year high of $154.24.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, August 4th. The specialty pharmaceutical company reported $3.71 earnings per share for the quarter, beating the consensus estimate of $3.11 by $0.60. The company had revenue of $562.44 million during the quarter, compared to analysts’ expectations of $503.19 million. Jazz Pharmaceuticals had a return on equity of 20.47% and a net margin of 6.01%. The business’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $4.05 earnings per share. Sell-side analysts forecast that Jazz Pharmaceuticals will post 11.08 earnings per share for the current year.

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 500 shares of the stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $134.90, for a total value of $67,450.00. Following the transaction, the chief executive officer now owns 336,680 shares in the company, valued at $45,418,132. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Bruce C. Cozadd sold 3,000 shares of the stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $130.00, for a total value of $390,000.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 3,863 shares of company stock worth $503,644. Corporate insiders own 4.60% of the company’s stock.

A number of large investors have recently made changes to their positions in the business. AQR Capital Management LLC lifted its holdings in shares of Jazz Pharmaceuticals by 19.7% in the first quarter. AQR Capital Management LLC now owns 2,353,827 shares of the specialty pharmaceutical company’s stock valued at $234,771,000 after purchasing an additional 387,575 shares in the last quarter. LSV Asset Management lifted its holdings in shares of Jazz Pharmaceuticals by 19.5% in the second quarter. LSV Asset Management now owns 2,225,431 shares of the specialty pharmaceutical company’s stock valued at $245,554,000 after purchasing an additional 363,015 shares in the last quarter. Thompson Siegel & Walmsley LLC bought a new position in shares of Jazz Pharmaceuticals in the second quarter valued at approximately $36,250,000. Point72 Asset Management L.P. lifted its holdings in shares of Jazz Pharmaceuticals by 1,424.8% in the second quarter. Point72 Asset Management L.P. now owns 346,139 shares of the specialty pharmaceutical company’s stock valued at $38,193,000 after purchasing an additional 323,439 shares in the last quarter. Finally, Sarissa Capital Management LP lifted its holdings in shares of Jazz Pharmaceuticals by 72.5% in the first quarter. Sarissa Capital Management LP now owns 765,000 shares of the specialty pharmaceutical company’s stock valued at $76,301,000 after purchasing an additional 321,500 shares in the last quarter. Institutional investors and hedge funds own 92.82% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Featured Story: Trading signals using Bollinger bands

The Fly

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.